In 2022, the latest clinical trial published on “Blood” found that the ORR of PD-L1 inhibitor Durmalumab combined with Azacytidine in the treatment of HR-MDS was 61.5%, the ORR of Azacytidine alone was 47. The gene discussed is CD274; the disease is myelodysplastic syndrome.